Join us for a high-impact workshop featuring two of the most influential figures in modern biotechnology. This session explores the critical synergy between DNA synthesis technology and the future of biological engineering.
In this webinar you will:
Learn how synthetic DNA is transforming the markets for DNA writing and sequencing.
Understand the process of converting streamlined genetic code into functional proteins.
Explore how the long-term evolution of “writing” biology could help address global challenges.
Webinar Registration
Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions.
Enter Details Header
Enter Details Subheader
Moderator
Prof. Walid M. El-Sharoud
Leader of the Synthetic Biology Group, Mansoura University, and CoSET, Benha National University, Egypt
Speaker
Dr. Emily Leproust
CEO & Co-Founder of Twist Bioscience
An early pioneer in the high-throughput synthesis and sequencing of DNA, Emily Leproust, Ph.D., is disrupting markets to enable the exponential growth of DNA-based applications across chemicals/materials, diagnostics, therapeutics, food and digital data storage.
Speaker
Prof. George Church
Professor of Genetics, Harvard Medical School & MIT
A founding father of genomics, Dr. Church co-initiated the Human Genome Project and has pioneered breakthrough technologies in CRISPR, protein engineering, and aging reversal.
Enter Presenter 4 Header
Enter Presenter 4 Name
Enter Presenter 4 Title
Guannan Wang, PhD, Senior Research Investigator, discusses how they are
identifying the driver mutations and clinically actionable biomarkers in all common canine cancers, to arm
veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict
treatment response, ultimately enabling precision medicine in canine oncology.
Enter Presenter 5 Header
Enter Presenter 5 Name
Enter Presenter 5 Title
Guannan Wang, PhD, Senior Research Investigator, discusses how they are
identifying the driver mutations and clinically actionable biomarkers in all common canine cancers, to arm
veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict
treatment response, ultimately enabling precision medicine in canine oncology.
Enter Presenter 6 Header
Enter Presenter 6 Name
Enter Presenter 6 Title
Guannan Wang, PhD, Senior Research Investigator, discusses how they are
identifying the driver mutations and clinically actionable biomarkers in all common canine cancers, to arm
veterinary clinicians with better prognostic information, target therapeutic options, and markers to predict
treatment response, ultimately enabling precision medicine in canine oncology.
